I
Index Pharmaceuticals
Biotech & Life Sciences · Solna kommun, Sweden · Founded 2000
Developing drugs to treat inflammatory bowel disease that can help patients return to a normal life MoreLess
InDex Pharmaceuticals Holding AB is a biopharmaceutical company listed on the Nasdaq First North Growth Market. The company focuses on developing innovative treatments for immunological disorders, with a particular emphasis on ulcerative colitis, a chronic inflammatory bowel disease. The Group includes InDex Pharmaceuticals AB and its wholly-owned subsidiary, InDex Diagnostics AB.
The primary product in InDex Pharmaceuticals' pipeline is cobitolimod, a drug designed to treat moderate to severe left-sided ulcerative colitis. Cobitolimod has a unique mechanism of action, which aims to provide effective and safe treatment options for patients who have limited alternatives. The company is currently preparing for a Phase III clinical trial to further evaluate the drug's efficacy and safety.
InDex Pharmaceuticals serves patients suffering from immunological disorders, particularly those with ulcerative colitis. The company operates in the biopharmaceutical market, which involves the development and commercialization of drugs based on biological sources.
The business model of InDex Pharmaceuticals revolves around research and development (R&D) of new drug candidates. The company invests heavily in clinical trials to ensure the safety and efficacy of its products. Revenue is generated through the successful commercialization of these drugs, either by bringing them to market directly or through partnerships and licensing agreements with larger pharmaceutical companies.
InDex Pharmaceuticals makes money by advancing its drug candidates through the clinical trial phases and eventually obtaining regulatory approval for market release. Once approved, the company can either sell the drugs directly to healthcare providers and patients or license the rights to other pharmaceutical companies in exchange for royalties and milestone payments.
Keywords: biopharmaceutical, ulcerative colitis, immunological disorders, cobitolimod, clinical trials, Nasdaq First North, drug development, R&D, healthcare, licensing.
Company overview
Index Pharmaceuticals company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2000
- Headquarters
- Solna kommun, Sweden
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 57.4
Valuation & funding
Index Pharmaceuticals funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Mar 2020 | $242K | — | Vinnova | — |
| GRANT✓Other financing | Mar 2018 | $55K | — | European Innovation Council | — |
| IPO✓Exit | Oct 2016 | $0 | — | Undisclosed | — |
| GRANTOther financing | May 2016 | $218K | — | Vinnova | — |
| EARLY VC✓Equity / VC | Mar 2014 | $17M | $66M | NeoMed | — |
| EARLY VC✓Equity / VC | Jan 2011 | Industrifonden · SEB Venture Capital | — | ||
| SPINOUT✓Other financing | Oct 2000 | Karolinska Institute · KI Science Park | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Index Pharmaceuticals website traffic
Latest recorded traffic for Index Pharmaceuticals is 1.3K monthly website visits, down 67.5% over the last three months. Index Pharmaceuticals's team grew 0% over the past year.
Comparisons
Index Pharmaceuticals compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 XenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform |
Nantes, France | Operational | 22 | $29M | $88M |
 Asgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming |
Lund Municipality, Sweden | Operational | |||
 AntegenesGenetic tests for personalized cancer risk prevention |
Tartu, Estonia | Operational | |||
 Blueprint GeneticsUses Next Generation Sequencing (NGS) to perform diagnostics on genetic diseases |
Espoo, Finland | Operational | |||
 BioNTechDevelops personalized immunotherapies with a focus on cancer medicine |
Mainz, Germany | Operational | |||
 Scenic BiotechGenetic modifier therapies for rare inherited diseases |
Amsterdam, Netherlands | Operational | |||
 ScancellClinical-stage immunotherapies for difficult-to-treat cancers |
Oxford, United Kingdom | Operational | |||
 Oryzon GenomicsDevelops diagnostic and therapeutic tools |
Cornellà de Llobregat, Spain | Operational |
Talent graph
Index Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Index Pharmaceuticals has talent and traffic
team presence
In the news
Latest news about Index Pharmaceuticals
Recent press, funding announcements, and product moves mentioning Index Pharmaceuticals — open to read from the original sources.
Market sentiment
What the market is saying about Index Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about Index Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Index Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.